Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data.

Sun Hyong YouByung Joo ChaeYong Hwa EomTae-Kyung YooYong-Seok KimJeong Soo KimWoo Chan Park

Published in: Journal of breast cancer (2018)

Our findings showed that anti-HER2 therapy was less beneficial for treatment of triple-positive breast cancer than for HER2-enriched subtypes of breast cancer, and the triple-positive subtype had a distinct prognosis.

Keyphrases

positive breast cancer
end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
electronic health record
big data
machine learning
mesenchymal stem cells
young adults
bone marrow
smoking cessation